Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
1 clinical trials · Condition
◉ Watch Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
| Record | Firm | Date |
|---|---|---|
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553) | Mayo Clinic | 2017-05-17 |
Track Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative automatically
Every clearance here is in the API, with alerts when new ones post.